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esponsibility of InsAbstract Hypoxia, or the lack of oxygen, has multiple impacts on the vascular system. The major
molecular sensors for hypoxia at the cellular level are hypoxia inducible factor and heme
oxygenase. Hypoxia also acts on the vasculature directly conveying its damaging effects through
disruption of the control of vascular tone, particularly in the coronary circulation, enhancement of
inﬂammatory responses and activation of coagulation pathways. These effects could be particularly
detrimental under pathological conditions such as obstructive sleep apnea and other breathing
disorders.
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Hypoxia is the term describing a state of lack of oxygen
endangering cell function. This condition can occur in four
main ways: (1) Hypoxic hypoxia, caused by an insufﬁcient
oxygen concentration in the air in the lungs, which is common
during sleep apnea, when the diffusion of oxygen to the blood
is reduced or in high altitude sickness; (2) Hypoxemic hypoxia,
occurring when the blood has reduced transport capacity as
seen in carbon monoxide poisoning when hemoglobin cannot
carry as much oxygen; (3) Stagnant hypoxia results when the
cardiac output does not match the demands of the body and
the ﬂow is not sufﬁcient to deliver enough oxygenated blood
to the tissue; and (4) Histotoxic hypoxia, when the cells cannot
utilize the available oxygen, for example during cyanide
poisoning when oxygen cannot be used to produce ATP as
the mitochondrial electron transport is inhibited1. Whatever
the cause, a reduction in oxygen concentration in the arterial
blood will trigger the chemoreceptors of the carotid body and
initiate a major activation of the sympathetic system; this
causes pronounced vasoconstriction throughout the body, and
can lead to a rapid rise in arterial blood pressure2–5. A local
shortage in oxygen supply also sets in motion a number of
immediate local (as opposed to reﬂex) changes leading to
vasoconstriction and vasodilatation which involve both
endothelial and vascular smooth muscle cells.2. Oxygen sensing
The sensor(s) responsible for the acute vascular response to
hypoxia is/are elusive. In endothelial cells, hypoxia can
destabilize eNOS mRNA by a mechanism involving Rho
kinase6. Oxidation of tetrahydrobiopterin, a co-factor of
eNOS, promotes ROS production by eNOS7,8. At the level
of the vascular smooth muscle, the production of reactive
oxygen species (ROS) during hypoxia will attenuate relaxa-
tions to nitric oxide, as ROS scavenge NO9,10. For more long-
term effects of hypoxia on the vascular wall, major players
appear to be heme oxygenase (HO) and hypoxia inducible
factor (HIF).
2.1. Reactive oxygen species
ROS may be signaling molecules during the response to
hypoxia. During the latter, the mitochondrial complex III
produces ROS11,12. In addition, NADPH oxidase (NOX),
which belongs to a class of proteins that transfer electrons
across membranes13, underlies the increase of ROS during
hypoxia14. The ROS level changes upon exposure to
hypoxia15,16, this change may modulate the activity of
several targets to cause either relaxations or contractions,
including soluble guanylyl cyclase (sGC)17, potassium and
calcium channels (such as sarcoplasmic reticulum calcium
ATPase)18,19. ROS can also stabilize hypoxia inducible factors
by inhibiting prolyl hydroxylase20,21.
There are number of potential sources that generate ROS,
among which the isoforms of NAD(P)H oxidase, which
contain a subunit with a ﬂavin system transferring electrons
to cytochrome b558
22. In smooth muscles of bovine large and
resistance arteries, hypoxia increases the superoxide anion
level, a response inhibited by diphenylene iodonium (NOXinhibitor)23. The latter drug also attenuates the hypoxic
response in the pulmonary artery of cats23. Another major
source of ROS is the electron transport chain of the mito-
chondria, in which the NADH dehydrogenase of complex I
and the Q cycle of complex III are sensitive to rotenone and
myxothiazole, respectively. These agents attenuate the
increased ROS generation stimulated by hypoxia in cultured
rat pulmonary arterial smooth muscles and reduce the
hypoxia-elicited vasoconstriction in perfused rat lungs24,25.
Other enzymes that can produce ROS include xanthine
oxidase26, cytochrome P-45027, cyclooxygenase28 and nitric
oxide synthase29.2.2. Heme oxygenase
HO is responsible for the breakdown of heme. Three isoforms
of this enzyme have been identiﬁed. HO-1 is the inducible
isoform, with anti-atherosclerotic and anti-myotrophic prop-
erties30. HO-2 is expressed constitutively in most tissues31; in
the mouse, its deletion results in impaired immunity, abnormal
oxygen sensing and ejaculatory abnormalities32. HO-3 is
expressed in several tissues but its function is less well
characterized31,33,34. Hypoxemia enhances the expression of
HO-135,36. The enzyme is tightly associated with large con-
ductance calcium activated potassium channel (BKCa) in the
carotid body and its activation in response to hypoxia causes
depolarization in the glomus cells37, implying a modulatory
role in reﬂex chemoreception. By contrast, in HO-2 knockout
mice, the oxygen sensing ability of the carotid body is not
affected signiﬁcantly38.
In all tissues, HO-1 and HO-2 release carbon monoxide and
iron during the metabolism of heme39,40. Carbon monoxide
can in turn activate sGC leading to the production of cyclic
guanosine monophosphate (cGMP) and relaxation of vascular
smooth muscle41. The level of activity of HO-1 helps to
regulate vascular tone. Thus, up-regulation of HO-1 reduces
arterial blood pressure and prevents endothelial dysfunction in
the spontaneous hypertensive rat42.2.3. Hypoxia inducible factor
More prolonged effects, especially at the genomic level, of
hypoxia depend on the over-expression of HIF, a dimer
consisting of a and b subunits43. The a subunit is expressed
constitutively but it is susceptible of oxygen-dependent post-
translational modiﬁcations. When the oxygen supply is sufﬁ-
cient (normoxia), HIF is hydroxylated by prolyl-hydroxylase
and degraded through an ubiquitin-dependent pathway43,44.
Prolyl-hydroxylase is inactivated when oxygen is insufﬁcient,
resulting in HIF accumulation in the cells. This mechanism
explains the oxygen sensing ability of the factor44. There are
three isoforms of the a subunit, HIF-1a, HIF-2a and HIF-3a.
When not degraded, HIF-1a binds to HIF-1b and activates a
number of genes. HIF is a powerful transcription factor and
promotes transcription of genes associated with angiogenesis
(vascular endothelial growth factors)45 and metalloprotei-
nases46 and metabolism (glucose transporter 1)43. HIF-2a is
responsible for erythropoietin production in response to
hypoxia47. HIF-3a is not well characterized but is more
abundant in tissues such as lung epithelial cells48.
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Upon exposure to hypoxia, both endothelial and vascular
smooth muscle cells rapidly respond in manners which involve
both acute and genomic changes that can lead to either
vasodilatation or vasoconstriction.3.1. Vascular tone
In vitro, the response to hypoxia can be monophasic, biphasic
or triphasic and varies among preparations of different
vascular beds. The monophasic response is a sustained con-
traction immediately after the induction of hypoxia49, the
biphasic response usually is a transient contraction followed
by a potent relaxation50,51 and the triphasic response involves
a transient contraction phase, followed by a transient relaxa-
tion phase and then a sustained contraction52,53.3.2. Pulmonary circulation
In pulmonary arteries, hypoxia causes a triphasic response ending
with a sustained phase of contraction52 and is termed ‘‘hypoxic
pulmonary vasoconstriction’’. This phenomenon is observed in
isolated systemic or pulmonary arteries across many species
including reptiles, birds and mammals53,54. Its physiological role
is to adjust the ventilation/perfusion ratio by diverting blood to
regions of the lung with adequate oxygen supply55. However
sustained hypoxic constrictions may lead to pulmonary hyperten-
sion; the latter is a dramatic pathological situation still in search of
an appropriate cure55,56. The acute phase of hypoxic constriction
of pulmonary blood vessels is endothelium-dependent57,58, and
ultimately results from the activation of Rho kinase leading to
calcium sensitization in the vascular smooth muscle59. It is
enhanced by inhibitors of NOS and phosphodiesterase V60.
Metallothionein, a protein responsible for zinc homeostasis, may
also be involved, since zinc chelation inhibits the contractile
response in pulmonary arteries61. As regards the sustained phase
of hypoxic constriction in the pulmonary circulation, cyclic
adenosine diphosphate ribose (cADPR), a molecule that mod-
ulates the activity of ryanodine receptors, appears to be respon-
sible62. Indeed, hypoxia increases the production of cADPR,
which facilitates calcium release from the sarcoplasmic reticu-
lum63. Furthermore, the cADPR antagonist, 8-bromo-cADPR,
abolishes the sustained phase of the hypoxic response64. These
changes work in conjunction with calcium sensitization (also
induced by hypoxia51) to produce hypoxic constriction.Fig. 1 Involvement of cyclooxygenase in hypoxic augmentation
in isolated porcine coronary arteries. Preparations with (þEC)
endothelium were incubated with either vehicle (control), indo-
methacin (105 M) or S18886 (107 M). Preparations without
endothelium (EC) were studied in parallel. The rings were
contracted to endothelin-1 (3 109108 M) before applying
hypoxia. The data are expressed as % of the reference contraction
to 60 mM KCl obtained at the beginning of the experiment and
shown as means 7SEM; n¼6; Po0.05 vs. the respective þEC
control, ]Po0.001 vs. the respective EC.3.3. Systemic circulation
Endothelium-dependent augmentation of contraction by acute
exposure to hypoxia has been observed in femoral and
coronary arteries of dogs58,65–67, pigs51 and humans68. This
contractile response to hypoxia occurs in quiescent prepara-
tions but is signiﬁcantly augmented in contracted preparations
regardless of the contracting agents used. In addition, it is
proportional to the level of the vasoconstriction immediately
before hypoxia is applied58,66 and hence this response to
hypoxia is termed ‘‘hypoxic augmentation’’. The endothelial
cells play an important role in the genesis of the vasocon-
strictor response to hypoxia51,58,66,69.The exact mechanism(s) underlying hypoxic endothelium-
dependent augmentation of contractions/constrictions of coron-
ary arteries is not fully understood. However the release of NO
appears to be involved in the phenomenon. Bioassay studies on
canine coronary arteries demonstrated that a diffusible substance
released by the endothelium contributes to hypoxic augmenta-
tion70. Further studies in the same artery demonstrated that a
NOS inhibitor, a NO scavenger and an inhibitor of soluble
guanylyl cyclase abolished the response66. In the porcine cor-
onary artery, incubation with NO donors (detaNONOate and
sodium nitroprusside) restores the hypoxic augmentation in
preparations without endothelium, which is not seen with a
cGMP analog or atrial natriuretic peptide, implying an involve-
ment of NO but an independency of cGMP51. The lack of effects
of protein kinase G and A inhibitors and insigniﬁcant changes in
cGMP level further suggested a cGMP independent pathway
activated by soluble guanylyl cyclase under hypoxic conditions51.
The different actions of NO concur to make it a powerful
endogenous vasodilator71–73. Hence, its involvement in mediating
endothelium-dependent contractions seems paradoxical51,58,65,66.
Endothelium-derived contracting factors (EDCF, vasoac-
tive substances that are released from the endothelium and can
causes contraction in the vascular smooth muscle74)
possibly could contribute to endothelium-dependent hypoxic
augmentation. The involvement of endothelin-1 is doubtful, as
bosentan, a non-selective ET receptor antagonist75, lacked
signiﬁcant effects on hypoxic augmentation in the porcine
coronary artery51. Earlier bioassay studies had also made a
contribution of the peptide unlikely76. A systematic analysis51
using pharmacological inhibitors ruled out the involvement of
reactive oxygen species and uridine adenosine tetraphosphate.
However, vasoconstrictor cyclooxygenase products appear to
be partially involved, as the inhibitor of cyclooxygenase,
indomethacin, and the TP receptor antagonist, S18886, reduce
hypoxic augmentation in porcine coronary arteries contracted
with endothelin-1 (Fig. 1). Although the intracellular concen-
tration of the key activator ion, calcium, is not changed
Fig. 2 A summary of the two endothelium-dependent pathways
activated in hypoxic augmentation, which involves cyclooxygen-
ase (COX) and endothelium nitric oxide synthase (eNOS), with
the latter being the dominating one. On the one hand, endothe-
lium-derived contracting factors (EDCFs) are released and acti-
vate thromboxane-prostanoid receptors (TP), which partly
contribute to the hypoxic augmentation. On the other hand,
nitric oxide (NO) activates soluble guanylyl cyclase (sGC) through
a cGMP-independent mechanism, which involves activation of
Rho kinase and calcium (Ca2þ) sensitization, but is independent
of calcium inﬂux from the extracellular environment.
C.K. Chan, P.M. Vanhoutte4acutely in porcine coronary arteries during hypoxia51,77, Rho
kinase inhibitors diminish hypoxic augmentation and hence
calcium sensitization is likely to be involved (Fig. 2)51.
Hypoxia can affect vascular tone through actions on ion
channels, but these result in relaxation rather than contrac-
tion. Thus, hypoxia causes hyperpolarization in primary
cultures of porcine coronary smooth muscles by opening
KATP channels
78. In human coronary myocytes, hypoxia
causes activation of KATP channels and the subsequent closure
of voltage-gated Ca2þ channels79.
Hypoxia also exert chronic effects on the vasculature.
A number of studies have pointed out that the viability and
proliferation of vascular smooth muscle cells are enhanced
after chronic hypoxia treatment. This can be attributed to the
augmented production by the vascular smooth muscle cells of
platelet derived growth factor and ﬁbroblast growth factor,
which activate the mTOR (mammalian target of rapamycin)
pathway80 as well as telomerase, extending lifespan81.3.4. Inﬂammation
Hypoxia also increases the expression of P-selectin, E-selectin,
intercellular adhesion molecules-1 (ICAM-1) and vascular cell
adhesion molecule-1 (VCAM-1) on the endothelium and
augment the permeability of the endothelial barrier82.
P-selectin is stored in Weibel–Palade bodies along with von
Willebrand factor (a procoagulant). It is released acutely
without de novo protein synthesis when the cells are exposed
to hypoxia83. P-selectin increases the recruitment of neutro-
phils from the blood, resulting in their migration into thevascular smooth muscle. The release of von Willebrand factor
reduces the ﬂuidity of the blood84,85. In addition, the endothe-
lial expression of pro-inﬂammatory cytokines such as inter-
leukin-6, interleukin-1a, interleukin-8 and MCP-1 is also
increased under hypoxia86.
3.5. Coagulation
Upon exposure to hypoxia, the release of thrombomodulin,
which normally inhibits the formation of thrombin and
subsequently of the cross-linked ﬁbrin clot, by the endothe-
lium is reduced87, whereas plasminogen activator inhibitor-1
(PAI-1, which inhibits ﬁbrinolysis) is up-regulated88,89. More-
over, prostacyclin released by the endothelium cannot exert
its anti-aggregatory effect on platelets because the activity
of its downstream mediator, adenylyl cyclase, is reduced by
hypoxia90,91. As a result, cross-linked ﬁbrin clots are formed
on the surface of endothelium, and this sets off the coagula-
tion cascade.4. Physiopathological implications
There are several conditions or diseases where hypoxia is
secondary to malfunction of the respiratory system. Hypoxic
augmentation signiﬁcantly reduces the blood supply to the
cardiac muscle in the coronary circulation. In dogs, this occurs
in vivo only and in coronary arteries that have been subjected
previously to ischemia–reperfusion injury65. Considering that the
hypoxic augmentation response can be repeated consistently even
after several episodes of exposure to hypoxia58, this phenomenon
could be important in patients with chronic obstructive pulmon-
ary disease or asthma or high altitude sickness, when the oxygen
content in the blood is reduced. It may be particularly relevant
for patients suffering from sleep apnea.
Obstructive sleep apnea is the closure of the respiratory
tract during sleep which leads to suffocation of the patient.
This occurs because the control of the muscles of the upper
respiratory tract is lost. As a result the latter collapses and less
air can pass through, resulting in a state of hypoxic hypoxia.
Usually this type of hypoxia lasts only for a short period of
time (seconds to minutes) as the patient is aroused reﬂexly by
the low oxygen level92 and regains control of the respiratory
tract muscles, alleviating hypoxia. However, this cycle of
hypoxia and arousal occurs many times during the night and
results in severe intermittent hypoxia93. The hemodynamic
stress in patients with sleep apnea is actually correlated with
the severity of hypoxia rather than with the arousal events94,
which suggests the destructive role of hypoxia on the vascular
system. In such patients, pro-inﬂammatory cytokines, oxida-
tive stress, apoptosis of endothelial cells and angiotensin II
levels are increased9,95. In rats, intermittent hypoxia causes an
increase in arterial pressure and this can be attenuated with an
angiotensin II receptor (AT1) inhibitor
96, implying that the
chronic effects of intermittent hypoxia involves the production
of vasoconstrictor peptides. In humans, a severity-dependent
association between sleep-disordered breathing and hyperten-
sion, which is a common risk factor for cardiovascular
events97,98, is established99. Furthermore, in a twelve year
follow up study, the fatal cardiovascular events in patients
with obstructive sleep apnea were approximately eight times
more frequent than in control subjects, and the group treated
Hypoxia, vascular smooth muscles and endothelium 5with continuous positive airway pressure to prevent the body
entering the hypoxic state have risks comparable to those of
the control group100.5. Conclusions
At the cellular level, hypoxia can be detected by enzymes
producing reactive oxygen species, heme oxygenase and
hypoxia inducible factor. Both endothelial and vascular
smooth muscle cells respond to this challenge. In certain
blood vessels, hypoxia favors contraction of the former in
an endothelium-dependent manner. Although the mediators
involved are still illusive, such endothelium-dependent hypoxic
response leads to increases in vascular tone, causing long-term
or acute constriction in the pulmonary and coronary circula-
tions, respectively. In addition, inﬂammatory pathways are
activated leading to increased recruitment of immune cells and
release of cytokines, resulting in chronic dysfunction/damage
of the vascular wall. This dysfunction in vivo may be further
enhanced by the activation of coagulation cascade, reducing
the blood ﬂow further and allowing more damage to be done.
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